An ultrasensitive colorimetric test for the detection of somatic rare mutations in DNA
- 21 January 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (5), 2973-2979
- https://doi.org/10.1039/c9nr10030j
Abstract
Targeted therapies for cutaneous melanoma, such as those based on specific BRAF inhibitors, have improved the treatment and enhanced the survival rate of patients who harbor the V600E point mutation in the BRAF gene. However, tissue biopsies to characterize BRAF mutation status are prone to sampling bias, due to the intrinsic heterogeneity of a tumor mass. In contrast, blood biopsies, which analyze circulating tumor DNA (ctDNA), offer the most complete and sensitive characterization of the mutation status of a tumor, provide early and more accurate diagnosis, but they require instrumental and costly molecular tests. Therefore, the development of low-cost but highly sensitive tests for the non-invasive identification of BRAFV600E mutation in ctDNA would be of great clinical utility as a routine screening for the early identification of responsive patients and the follow-up of targeted therapy's response. The present work developed a naked-eye, inexpensive, yet very specific colorimetric assay, whose sensitivity is suitable for the detection of BRAFV600E rare mutation in ctDNA. Such test potentially may detect at an early stage the mutation in the tumor mass, when the first mutated cells appear in the blood, by using minimal instrumentation and thus enabling its widespread implementation in the clinics, even in local, minimally equipped laboratories. Indeed, the test detects 0.5% of BRAFV600E in an excess of BRAFWT DNA, which matches the sensitivity of some commercial instrumental assays. Such sensitivity is thus clinically relevant for diagnostic purposes, allowing the early identification of drug-sensitive patients.This publication has 34 references indexed in Scilit:
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsThe New England Journal of Medicine, 2012
- Intra-tumour heterogeneity: a looking glass for cancer?Nature Reviews Cancer, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II studyBritish Journal of Cancer, 2009
- Overview of Circulating Nucleic Acids in Plasma/SerumAnnals of the New York Academy of Sciences, 2008
- Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving BiochemotherapyClinical Cancer Research, 2007
- Circulating nucleic acids (CNAs) and cancer—A surveyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- Mutations of the BRAF gene in human cancerNature, 2002